CXCL10 and type 1 diabetes mellitus: Thus, as outlined in Figure 1, a well-timed partial deletion and reprogramming of T cells through short-term administration of anti-CD3 antibodies followed by the inhibition of T cell migration and islet re-infiltration via neutralization of the key inflammatory chemokine CXCL10 induces a persistent remission of T1D.